PWSA Blog

Gedeon Richter Now Recruiting for KITE-PWS Clinical Trial

You or someone you love could be part of developing new therapies for Prader-Willi syndrome. Learn about Gedeon Richter's research study KITE-PWS, also known as RGH-706-003, to evaluate an experimental drug for hyperphagia in people with Prader-Willi syndrome. The oral drug RGH-706 works by blocking melanin-concentrating hormone (MCH), which is a key part in the brain’s food seeking mechanism, to help reduce appetite.

To be in the study, participants must meet the following basic criteria:

  • Are at least 17 years of age
  • Have a diagnosis of PWS
  • Have a body weight of greater than 40 kg (88 lbs.) and less than 200 kg (450 lbs.)
  • Have had a stable body weight for the past 3 months
  • Have at least 1 consistent and reliable primary caregiver who can evaluate changes in the participant’s hyperphagia symptoms, mood, health, and behavior throughout the study
  • Do not have uncontrolled diabetes or diabetes that requires insulin

Medical history and other criteria will also be reviewed to determine eligibility. The study lasts 5-6 months and requires about 8 study visits. The study drug, tests, examinations, and study-related medical care are provided at no cost. Reimbursement for certain study-related expenses such as travel may also be available.

Click here to find more information about the study and contact Gedeon Richter's Medical Information Scientific Service at medinfo@richter.hu to inquire about participating.

Gedeon Richter also provided a list of doctors in the U.S. who can be contacted to provide more information about this clinical trial opportunity:

Share this!

Scroll to top